α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.

Abstract excerpt

α1 Antitrypsin deficiency (AATD) increases the risk of chronic obstructive pulmonary disease (COPD), liver disease and other conditions. Although it is not a rare disease, it is a condition rarely diagnosed because of unawareness by most healthcare providers who manage subjects at risk. Testing recommendations have been published and strongly suggest testing all subjects with confirmed COPD, cryptogenic liver...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to alpha 1-Antitrypsin
• Share to alpha 1-Antitrypsin Deficiency
• Share to Disease Progression